Arwa Nada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arwa Nada has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
David Askenazi
Department of Pediatrics, Division of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, USA
3 shared publicationsJohn D. Mahan
Department of Pediatrics, Division of Nephrology, Nationwide Children’s Hospital, The Ohio State University, Columbus, USA
3 shared publicationsJuan C. Kupferman
Department of Pediatrics, Division of Pediatric Nephrology & Hypertension, Maimonides Medical Center, Brooklyn, USA
3 shared publicationsLinzi Li
Department of Pediatrics, Division of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, USA
3 shared publications- Rupesh Raina
Department of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General Medical Center, Akron, USA
3 shared publications Russell L. Griffin
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, USA
3 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Springer Nature in npj Digital Medicine
A global framework for artificial intelligence education in medicine: international working group recommendations
- 9 September 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessA global framework for artificial intelligence education in medicine: international working group recommendations
- Open Access
- 6 September 2026
- Published by Springer Nature in Research Square
Development and Computational Validation of Neonatal Acute Kidney Injury Risk Model (PC-NAKI) using synthetic data: Hybrid Innovation and Clinical Framing
Background: Neonatal acute kidney injury (AKI) is common in critically ill infants and is independently associated with increased mortality, prolonged hospitalization, and significantly higher healthcare costs. Early identification of infants at risk for AKI remains challenging due to reliance on delayed biochemical markers and variability in clinical presentation. Most prior risk models have focused on postnatal variables alone, with limited integration of maternal and prenatal factors. Methods: We developed the Prediction Calculator of Neonatal Acute Kidney Injury (PC-NAKI) , a maternal-enhanced risk stratification tool that integrates maternal, perinatal, and early neonatal illness severity variables available within the first seven days of life. Candidate predictors were selected based on clinical plausibility and literature evidence and were assigned point values to generate a composite PC-NAKI score. To test model architecture and analytical workflows prior to clinical deployment, we performed structured computational validation using a synthetic cohort of 2,500 simulated neonates. Discrimination was assessed using area under the receiver operating characteristic curve (ROC-AUC), and calibration was evaluated via logistic mapping of scores to predicted probabilities along with decile analysis. Risk tiers were prespecified as Low (0–5), Moderate (6–10), High (11–15), and Very High (≥16). Results: In the synthetic cohort, PC-NAKI scores exhibited a broad range of values with distinct risk strata. Risk tier analysis demonstrated increasing AKI incidence across tiers. The PC-NAKI score achieved good discriminative performance (ROC-AUC = 0.747) for synthetic AKI outcomes. Calibration analyses showed close alignment between observed and predicted AKI probabilities across deciles of predicted risk, and the Brier score indicated satisfactory overall calibration. Synthetic tier performance demonstrated stepwise increases in AKI rates from the Low to Very High-risk categories, supporting the utility of tier-based risk stratification. Conclusions: PC-NAKI is a novel maternal-enhanced neonatal AKI risk score calculator that shows promising discrimination and calibration in synthetic validation. These results support the structural and analytical integrity of the model and provide a framework for subsequent retrospective and prospective real-world clinical validation. Early risk stratification using PC-NAKI could facilitate targeted AKI prevention strategies and may enhance clinical decision-making in vulnerable neonatal populations.
- 6 September 2026
- Published by Springer Nature in Research Square
Open AccessDevelopment and Computational Validation of Neonatal Acute Kidney Injury Risk Model (PC-NAKI) using synthetic data: Hybrid Innovation and Clinical Framing
Background: Neonatal acute kidney injury (AKI) is common in critically ill infants and is independently associated with increased mortality, prolonged hospitalization, and significantly higher healthcare costs. Early identification of infants at risk for AKI remains challenging due to reliance on delayed biochemical markers and variability in clinical presentation. Most prior risk models have focused on postnatal variables alone, with limited integration of maternal and prenatal factors. Methods: We developed the Prediction Calculator of Neonatal Acute Kidney Injury (PC-NAKI) , a maternal-enhanced risk stratification tool that integrates maternal, perinatal, and early neonatal illness severity variables available within the first seven days of life. Candidate predictors were selected based on clinical plausibility and literature evidence and were assigned point values to generate a composite PC-NAKI score. To test model architecture and analytical workflows prior to clinical deployment, we performed structured computational validation using a synthetic cohort of 2,500 simulated neonates. Discrimination was assessed using area under the receiver operating characteristic curve (ROC-AUC), and calibration was evaluated via logistic mapping of scores to predicted probabilities along with decile analysis. Risk tiers were prespecified as Low (0–5), Moderate (6–10), High (11–15), and Very High (≥16). Results: In the synthetic cohort, PC-NAKI scores exhibited a broad range of values with distinct risk strata. Risk tier analysis demonstrated increasing AKI incidence across tiers. The PC-NAKI score achieved good discriminative performance (ROC-AUC = 0.747) for synthetic AKI outcomes. Calibration analyses showed close alignment between observed and predicted AKI probabilities across deciles of predicted risk, and the Brier score indicated satisfactory overall calibration. Synthetic tier performance demonstrated stepwise increases in AKI rates from the Low to Very High-risk categories, supporting the utility of tier-based risk stratification. Conclusions: PC-NAKI is a novel maternal-enhanced neonatal AKI risk score calculator that shows promising discrimination and calibration in synthetic validation. These results support the structural and analytical integrity of the model and provide a framework for subsequent retrospective and prospective real-world clinical validation. Early risk stratification using PC-NAKI could facilitate targeted AKI prevention strategies and may enhance clinical decision-making in vulnerable neonatal populations.
- Open Access
- 10 August 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1)
An epidemiological assessment of hemodialysis, continuous kidney replacement therapy, and peritoneal dialysis in pediatric acute kidney injury patients
Acute Kidney Injury (AKI) is common among pediatric patients, affecting 10-35% of critically ill children and 34% of non-critically ill children [1]. Pediatric AKI is associated with higher risk of...
- 10 August 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1)
Open AccessAn epidemiological assessment of hemodialysis, continuous kidney replacement therapy, and peritoneal dialysis in pediatric acute kidney injury patients
Acute Kidney Injury (AKI) is common among pediatric patients, affecting 10-35% of critically ill children and 34% of non-critically ill children [1]. Pediatric AKI is associated with higher risk of...
- Open Access
- 16 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (5) , 1275-1286
AI-powered insights in pediatric nephrology: current applications and future opportunities
Artificial intelligence (AI) is rapidly emerging as a transformative force in pediatric nephrology, enabling improvements in diagnostic accuracy, therapeutic precision, and operational workflows. By integrating diverse datasets—including patient histories, genomics, imaging, and longitudinal clinical records—AI-driven tools can detect subtle kidney anomalies, predict acute kidney injury, and forecast disease progression. Deep learning models, for instance, have demonstrated the potential to enhance ultrasound interpretations, refine kidney biopsy assessments, and streamline pathology evaluations. Coupled with robust decision support systems, these innovations also optimize medication dosing and dialysis regimens, ultimately improving patient outcomes. AI-powered chatbots hold promise for improving patient engagement and adherence, while AI-assisted documentation solutions offer relief from administrative burdens, mitigating physician burnout. However, ethical and practical challenges remain. Healthcare professionals must receive adequate training to harness AI’s capabilities, ensuring that such technologies bolster rather than erode the vital doctor-patient relationship. Safeguarding data privacy, minimizing algorithmic bias, and establishing standardized regulatory frameworks are critical for safe deployment. Beyond clinical care, AI can accelerate pediatric nephrology research by identifying biomarkers, enabling more precise patient recruitment, and uncovering novel therapeutic targets. As these tools evolve, interdisciplinary collaborations and ongoing oversight will be key to integrating AI responsibly. Harnessing AI’s vast potential could revolutionize pediatric nephrology, championing a future of individualized, proactive, and empathetic care for children with kidney diseases. Through strategic collaboration and transparent development, these advanced technologies promise to minimize disparities, foster innovation, and sustain compassionate patient-centered care, shaping a new horizon in pediatric nephrology research and practice. Graphical Abstract
- 16 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (5) , 1275-1286
Open AccessAI-powered insights in pediatric nephrology: current applications and future opportunities
Artificial intelligence (AI) is rapidly emerging as a transformative force in pediatric nephrology, enabling improvements in diagnostic accuracy, therapeutic precision, and operational workflows. By integrating diverse datasets—including patient histories, genomics, imaging, and longitudinal clinical records—AI-driven tools can detect subtle kidney anomalies, predict acute kidney injury, and forecast disease progression. Deep learning models, for instance, have demonstrated the potential to enhance ultrasound interpretations, refine kidney biopsy assessments, and streamline pathology evaluations. Coupled with robust decision support systems, these innovations also optimize medication dosing and dialysis regimens, ultimately improving patient outcomes. AI-powered chatbots hold promise for improving patient engagement and adherence, while AI-assisted documentation solutions offer relief from administrative burdens, mitigating physician burnout. However, ethical and practical challenges remain. Healthcare professionals must receive adequate training to harness AI’s capabilities, ensuring that such technologies bolster rather than erode the vital doctor-patient relationship. Safeguarding data privacy, minimizing algorithmic bias, and establishing standardized regulatory frameworks are critical for safe deployment. Beyond clinical care, AI can accelerate pediatric nephrology research by identifying biomarkers, enabling more precise patient recruitment, and uncovering novel therapeutic targets. As these tools evolve, interdisciplinary collaborations and ongoing oversight will be key to integrating AI responsibly. Harnessing AI’s vast potential could revolutionize pediatric nephrology, championing a future of individualized, proactive, and empathetic care for children with kidney diseases. Through strategic collaboration and transparent development, these advanced technologies promise to minimize disparities, foster innovation, and sustain compassionate patient-centered care, shaping a new horizon in pediatric nephrology research and practice. Graphical Abstract
- Open Access
- 5 June 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (7) , 1041-1043
KRT Designed for Infants: A Game Changer
An abstract is unavailable. This article is available as a PDF only.
- 5 June 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (7) , 1041-1043
Open AccessKRT Designed for Infants: A Game Changer
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 22 March 2024
- Published by Springer Nature in Pediatric Nephrology
- Vol. 39 (8) , 2505-2514
Utilizing electronic medical records alert to improve documentation of neonatal acute kidney injury
Background: Neonatal acute kidney injury (AKI) is a common yet underdiagnosed condition in neonates with significant implications for long-term kidney health. Lack of timely recognition and documentation of AKI contributes to missed opportunities for nephrology consultation and follow-up, potentially leading to adverse outcomes. Methods: We conducted a quality improvement (QI) project to address this by incorporating an automated real-time electronic medical record (EMR)-AKI alert system in the Neonatal Intensive Care Unit (NICU) at Le Bonheur Children’s Hospital. Our primary objective was to improve documentation of neonatal AKI (defined as serum creatinine (SCr) > 1.5 mg/dL) by 25% compared to baseline levels. The secondary goal was to increase nephrology consultations and referrals to the neonatal nephrology clinic. We designed an EMR-AKI alert system to trigger for neonates with SCr > 1.5 mg/dL, automatically adding AKI diagnosis to the problem list. This prompted physicians to consult nephrology, refer neonates to the nephrology clinic, and consider medication adjustments. Results: Our results demonstrated a significant improvement in AKI documentation after implementing the EMR-AKI alert, reaching 100% compared with 7% at baseline (p < 0.001) for neonates with SCr > 1.5 mg/dL. Although the increase in nephrology consultations was not statistically significant (p = 0.5), there was a significant increase in referrals to neonatal nephrology clinics (p = 0.005). Conclusions: Integration of an EMR alert system with automated documentation offers an efficient and economical solution for improving neonatal AKI diagnosis and documentation. This approach enhances healthcare provider engagement, streamlines workflows, and supports QI. Widespread adoption of similar approaches can lead to improved patient outcomes and documentation accuracy in neonatal AKI care. Graphical
- 22 March 2024
- Published by Springer Nature in Pediatric Nephrology
- Vol. 39 (8) , 2505-2514
Open AccessUtilizing electronic medical records alert to improve documentation of neonatal acute kidney injury
Background: Neonatal acute kidney injury (AKI) is a common yet underdiagnosed condition in neonates with significant implications for long-term kidney health. Lack of timely recognition and documentation of AKI contributes to missed opportunities for nephrology consultation and follow-up, potentially leading to adverse outcomes. Methods: We conducted a quality improvement (QI) project to address this by incorporating an automated real-time electronic medical record (EMR)-AKI alert system in the Neonatal Intensive Care Unit (NICU) at Le Bonheur Children’s Hospital. Our primary objective was to improve documentation of neonatal AKI (defined as serum creatinine (SCr) > 1.5 mg/dL) by 25% compared to baseline levels. The secondary goal was to increase nephrology consultations and referrals to the neonatal nephrology clinic. We designed an EMR-AKI alert system to trigger for neonates with SCr > 1.5 mg/dL, automatically adding AKI diagnosis to the problem list. This prompted physicians to consult nephrology, refer neonates to the nephrology clinic, and consider medication adjustments. Results: Our results demonstrated a significant improvement in AKI documentation after implementing the EMR-AKI alert, reaching 100% compared with 7% at baseline (p < 0.001) for neonates with SCr > 1.5 mg/dL. Although the increase in nephrology consultations was not statistically significant (p = 0.5), there was a significant increase in referrals to neonatal nephrology clinics (p = 0.005). Conclusions: Integration of an EMR alert system with automated documentation offers an efficient and economical solution for improving neonatal AKI diagnosis and documentation. This approach enhances healthcare provider engagement, streamlines workflows, and supports QI. Widespread adoption of similar approaches can lead to improved patient outcomes and documentation accuracy in neonatal AKI care. Graphical
- Open Access
- 19 December 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (2) , 285-309
Nutrition in Critically Ill Children with AKI on Continuous RRT: Consensus Recommendations
Background: Nutrition plays a vital role in the outcome of critically ill children, particularly those with AKI. Currently, there are no established guidelines for children with AKI treated with continuous RRT (CRRT). A thorough understanding of the metabolic changes and nutritional challenges in AKI and CRRT is required. Our objective was to create clinical practice points for nutritional assessment and management in critically ill children with AKI receiving CRRT. Methods: PubMed, MEDLINE, Cochrane, and Embase databases were searched for articles related to the topic. Expertise of the authors and a consensus of the workgroup were additional sources of data in the article. Available articles on nutrition therapy in pediatric patients receiving CRRT through January 2023. Results: On the basis of the literature review, the current evidence base was examined by a panel of experts in pediatric nephrology and nutrition. The panel used the literature review as well as their expertise to formulate clinical practice points. The modified Delphi method was used to identify and refine clinical practice points. Conclusions: Forty-four clinical practice points are provided on nutrition assessment, determining energy needs, and nutrient intake in children with AKI and on CRRT on the basis of the existing literature and expert opinions of a multidisciplinary panel.
- 19 December 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (2) , 285-309
Open AccessNutrition in Critically Ill Children with AKI on Continuous RRT: Consensus Recommendations
Background: Nutrition plays a vital role in the outcome of critically ill children, particularly those with AKI. Currently, there are no established guidelines for children with AKI treated with continuous RRT (CRRT). A thorough understanding of the metabolic changes and nutritional challenges in AKI and CRRT is required. Our objective was to create clinical practice points for nutritional assessment and management in critically ill children with AKI receiving CRRT. Methods: PubMed, MEDLINE, Cochrane, and Embase databases were searched for articles related to the topic. Expertise of the authors and a consensus of the workgroup were additional sources of data in the article. Available articles on nutrition therapy in pediatric patients receiving CRRT through January 2023. Results: On the basis of the literature review, the current evidence base was examined by a panel of experts in pediatric nephrology and nutrition. The panel used the literature review as well as their expertise to formulate clinical practice points. The modified Delphi method was used to identify and refine clinical practice points. Conclusions: Forty-four clinical practice points are provided on nutrition assessment, determining energy needs, and nutrient intake in children with AKI and on CRRT on the basis of the existing literature and expert opinions of a multidisciplinary panel.
- 16 March 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (7) , 1699-1700
Correction to: Low albumin levels are independently associated with neonatal acute kidney injury: a report from AWAKEN Study Group
- 16 March 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (7) , 1699-1700
Correction to: Low albumin levels are independently associated with neonatal acute kidney injury: a report from AWAKEN Study Group
- 18 October 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (7) , 1675-1686
Low albumin levels are independently associated with neonatal acute kidney injury: a report from AWAKEN Study Group
Background Data from adult and pediatric literature have shown an association between albumin levels and AKI. Whether hypoalbuminemia and neonatal AKI are associated has not been studied. Methods We evaluated the association of albumin with early (during the first postnatal week) and late (after the first postnatal week) AKI for 531 neonates from the Assessment of Worldwide AKI Epidemiology in Neonates (AWAKEN) database and for 3 gestational age (GA) subgroups: < 29, 29 to < 36, and ≥ 36 weeks GA. Results Low albumin levels were associated with increased odds of neonatal AKI; for every 0.1 g/dL decrease in albumin, the odds of late AKI increased by 12% on continuous analysis. After adjustment for potential confounders, neonates with albumin values in the lowest quartiles (< 2.2 g/dL) had an increased odds of early [Adjusted Odd Ratio (AdjOR) 2.5, 95% CI = 1.1–5.3, p < 0.03] and late AKI [AdjOR 13.4, 95% CI = 3.6–49.9, p < 0.0001] compared to those with albumin in the highest quartile (> 3.1 g/dL). This held true for albumin levels 2.3 to 2.6 g/dL for early [AdjOR 2.5, 95% CI = 1.2–5.5, p < 0.02] and late AKI [AdjOR 6.4, 95% CI = 1.9–21.6, p < 0.01]. Albumin quartiles of (2.7 to 3.0 g/dL) were associated with increased odds of late AKI. Albumin levels of 2.6 g/dL and 2.4 g/dL best predicted early (AUC = 0.59) and late AKI (AUC = 0.64), respectively. Analysis of albumin association with AKI by GA is described. Conclusions Low albumin levels are independently associated with early and late neonatal AKI. Albumin could be a potential modifiable risk factor for neonatal AKI.
- 18 October 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (7) , 1675-1686
Low albumin levels are independently associated with neonatal acute kidney injury: a report from AWAKEN Study Group
Background Data from adult and pediatric literature have shown an association between albumin levels and AKI. Whether hypoalbuminemia and neonatal AKI are associated has not been studied. Methods We evaluated the association of albumin with early (during the first postnatal week) and late (after the first postnatal week) AKI for 531 neonates from the Assessment of Worldwide AKI Epidemiology in Neonates (AWAKEN) database and for 3 gestational age (GA) subgroups: < 29, 29 to < 36, and ≥ 36 weeks GA. Results Low albumin levels were associated with increased odds of neonatal AKI; for every 0.1 g/dL decrease in albumin, the odds of late AKI increased by 12% on continuous analysis. After adjustment for potential confounders, neonates with albumin values in the lowest quartiles (< 2.2 g/dL) had an increased odds of early [Adjusted Odd Ratio (AdjOR) 2.5, 95% CI = 1.1–5.3, p < 0.03] and late AKI [AdjOR 13.4, 95% CI = 3.6–49.9, p < 0.0001] compared to those with albumin in the highest quartile (> 3.1 g/dL). This held true for albumin levels 2.3 to 2.6 g/dL for early [AdjOR 2.5, 95% CI = 1.2–5.5, p < 0.02] and late AKI [AdjOR 6.4, 95% CI = 1.9–21.6, p < 0.01]. Albumin quartiles of (2.7 to 3.0 g/dL) were associated with increased odds of late AKI. Albumin levels of 2.6 g/dL and 2.4 g/dL best predicted early (AUC = 0.59) and late AKI (AUC = 0.64), respectively. Analysis of albumin association with AKI by GA is described. Conclusions Low albumin levels are independently associated with early and late neonatal AKI. Albumin could be a potential modifiable risk factor for neonatal AKI.
- 6 September 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (6) , 1285-1300
Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant
Onco-nephrology is a recent and evolving medical subspecialty devoted to the care of patients with kidney disease and unique kidney-related complications in the context of cancer and its treatments, recognizing that management of kidney disease as well as the cancer itself will improve survival and quality of life. While this area has received much attention in the adult medicine sphere, similar emphasis in the pediatric realm has not yet been realized. As in adults, kidney involvement in children with cancer extends beyond the time of initial diagnosis and treatment. Many interventions, such as chemotherapy, stem cell transplant, radiation, and nephrectomy, have long-term kidney effects, including the development of chronic kidney disease (CKD) with subsequent need for dialysis and/or kidney transplant. Thus, with the improved survival of children with malignancy comes the need for ongoing monitoring of kidney function and early mitigation of kidney-related comorbidities. In addition, children with kidney transplant are at higher risk of developing malignancies than their age-matched peers. Pediatric nephrologists thus need to be aware of issues related to cancer and its treatments as they impact their own patients. These facts emphasize the necessity of pediatric nephrologists and oncologists working closely together in managing these children and highlight the importance of bringing the onco-nephrology field to our growing list of pediatric nephrology subspecialties.
- 6 September 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (6) , 1285-1300
Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant
Onco-nephrology is a recent and evolving medical subspecialty devoted to the care of patients with kidney disease and unique kidney-related complications in the context of cancer and its treatments, recognizing that management of kidney disease as well as the cancer itself will improve survival and quality of life. While this area has received much attention in the adult medicine sphere, similar emphasis in the pediatric realm has not yet been realized. As in adults, kidney involvement in children with cancer extends beyond the time of initial diagnosis and treatment. Many interventions, such as chemotherapy, stem cell transplant, radiation, and nephrectomy, have long-term kidney effects, including the development of chronic kidney disease (CKD) with subsequent need for dialysis and/or kidney transplant. Thus, with the improved survival of children with malignancy comes the need for ongoing monitoring of kidney function and early mitigation of kidney-related comorbidities. In addition, children with kidney transplant are at higher risk of developing malignancies than their age-matched peers. Pediatric nephrologists thus need to be aware of issues related to cancer and its treatments as they impact their own patients. These facts emphasize the necessity of pediatric nephrologists and oncologists working closely together in managing these children and highlight the importance of bringing the onco-nephrology field to our growing list of pediatric nephrology subspecialties.